HomeProductsBuilding BlocksHeterocyclic ScaffoldsPiperazinesCasopitant
Chemical structure of CAS 414910-27-3

Casopitant

CAS No.414910-27-3
MDL No.N/A
MFC30H35F7N4O2
MW616.60
InChI KeyXGGTZCKQRWXCHW-WMTVXVAQSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Casopitant is a piperidine compound.

CAS No.414910-27-3
Product NameCasopitant

Biological Targets

TACR1

Associated Conditions

Nausea and vomiting·Chemotherapy-induced nausea and vomiting·Nausea·Vomiting·Sleep Disorder·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.

The Lancet. Oncology • Vol. 10, Issue 6 • 2009
PMID: 19428297DOI: 10.1016/S1470-2045(09)70109-3

Disposition and metabolism of radiolabeled casopitant in humans.

Drug metabolism and disposition: the biological fate of chemicals • Vol. 37, Issue 8 • 2009
PMID: 19420128DOI: 10.1124/dmd.109.026781

Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer • Vol. 17, Issue 9 • 2009
PMID: 19205754PMC: PMC2726911DOI: 10.1007/s00520-008-0572-4

Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer • Vol. 17, Issue 9 • 2009
PMID: 19205755PMC: PMC2726912DOI: 10.1007/s00520-008-0571-5

Documentation

Similar Products